Avalyn Announces First Patient Dosed in AURA Phase 2 Clinical Trial Evaluating AP02, Inhaled Nintedanib, for the Treatment of Idiopathic Pulmonary Fibrosis

Avalyn Announces First Patient Dosed in AURA Phase 2 Clinical Trial Evaluating AP02, Inhaled Nintedanib, for the Treatment of Idiopathic Pulmonary Fibrosis

Published

News published by Avalyn Pharma concerning AP02 (inhaled nintedanib), administered via an optimized eFlow® Technology nebulizer.
 

Read the press release

Back to overview